The FDA has approved secukinumab (Cosentyx; Novartis) for the treatment of pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa (HS), the company announced. 1 The ...
Although FDA Commissioner Marty Makary promised “an exciting treatment” for autism, what the agency delivered was a label expansion for leucovorin to treat the ultrarare cerebral folate deficiency.
FDA worked with GSK to update Wellcovorin labelling for safe, effective use in adult and paediatric CFD-FOLR1 patients.
Marketing Surveillance (PMS), often referred to as Phase IV clinical trials, is the systematic and ongoing monitoring of a drug's safety, efficacy, and real-world performance after it receives ...
In another development, 25 states have petitioned to join a lawsuit and defend the EPA’s decision to rescind the climate endangerment finding ...
Not long after Novo Nordisk received an untitled letter from the FDA disputing certain elements of the first TV spot for its ...
Investors are scrutinizing the prospects for some drugs in the pipeline following a string of recent rejections from the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results